Innovations and Challenges in Clinical Trials and Translational Research in Hematologic Malignancies and Solid Tumors

Dear Colleagues,

This Special Issue focuses on contemporary clinical trials and clinical research strategies in hematology and oncology, with particular emphasis on methodological innovation and translational relevance. The scope includes early- and late-phase clinical trials, investigator-initiated studies, and biomarker-driven approaches aimed at improving patient selection, treatment personalization, and clinical outcomes. Contributions addressing adaptive and pragmatic trial designs, safety assessment, regulatory considerations, and the integration of real-world evidence into oncology research are particularly encouraged. Both hematologic malignancies and solid tumors are within scope, provided that studies offer clear clinical or translational implications. Original research articles, systematic reviews, and expert perspectives are welcomed, especially those highlighting challenges in trial conduct, patient-centered endpoints, and the clinical development of targeted and immune-based therapies. This Special Issue aims to foster high-quality evidence that bridges innovation with real-world clinical practice in cancer care.

Dr. Abdurraouf Mokhtar Mahmoud
Dr. Clara Deambrogi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.